Streetbeat News

PRPO

Precipio, Inc.

https://www.precipiodx.com

Industry

Medical - Diagnostics & Research

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

Open

6.00

Mkt cap

9.1M

Volume

11K

High

6.40

P/E Ratio

-3.39

52-wk high

7.60

Low

6.00

Div yield

N/A

52-wk low

4.31

Precipio, Inc. (NASDAQ:PRPO) has announced a 28% increase in Q3-2023 revenues to $4.5M, up from $3.5M in Q2-2023, and more than double the $2.2M from Q3-2022. The company attributes this growth to its pathology and products divisions, as well as efficiency and cost reduction initiatives. The company is approaching a $20M run rate and expects its operating cash flow to approach breakeven.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2023 | 1:07 pm

Precipio Inc has regained compliance with the Nasdaq Bid Price Rule, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 8:38 pm

Precipio's Q3 cash burn from unaudited operations has declined by 59% YoY, from $2.5M to approximately $1M.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2023 | 2:06 pm

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) expects new customer orders to bring total Q4 HemeScreen revenues to an estimated $1.2M, which is within $300,000 of quarterly cash flow breakeven. The company's conversion rate data shows a high close rate once the sales team presents the product and its value proposition. Precipio's CEO, Ilan Danieli, stated that the company's HemeScreen product line stands above competition in terms of robustness, ease of use, and economics.

Portfolio Pulse from Benzinga Newsdesk

September 28, 2023 | 1:06 pm

Precipio, Inc. (NASDAQ:PRPO) has announced that it has reduced the revenue required from its products division to reach breakeven from $8M to $6M annually, or $1.5M per quarter, 25% below previous estimates. This is due to increased pathology revenue and recent operational efficiencies. The company anticipates reaching cash flow breakeven sooner due to increased pathology revenues, improved gross margins, and the impact of cost reduction initiatives.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 3:01 pm

Precipio has implemented a 1-for-20 reverse stock split, which is now in effect. This action is typically taken by companies to increase the market price of their shares.

Portfolio Pulse from Charles Gross

September 22, 2023 | 9:56 am

Precipio has taken the final step towards regaining compliance with Nasdaq's listing requirements. The company's stock, PRPO, is expected to remain listed on the exchange.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 1:01 pm

Several healthcare stocks experienced significant movement in Tuesday's after-market session. Notable gainers included Axcella Health (AXLA), Carmell Therapeutics (CTCX), ContraFect (CFRX), Infinity Pharmaceuticals (INFI), Beyond Air (XAIR), and Healthcare Triangle (HCTI). On the other hand, FibroGen (FGEN), TransCode Therapeutics (RNAZ), Precipio (PRPO), AEON Biopharma (AEON), Vaccinex (VCNX), and NanoVibronix (NAOV) saw their stocks decline.

Portfolio Pulse from Benzinga Insights

August 29, 2023 | 9:31 pm

Precipio (NASDAQ:PRPO) is set to release its latest quarterly earnings report on August 17, 2023. Analysts estimate an earnings per share (EPS) of $-0.10. The company's past performance shows a mixed impact on the share price post-earnings release. The stock is currently trading at $0.359, down 71.12% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

August 16, 2023 | 4:01 pm

Precipio has launched its HemeScreen BCR-ABL 2.0 assay, a product that offers superior clinical coverage, workflow simplicity, and cost-effectiveness. The product is the only panel on the market that provides quantitative coverage of four clinically relevant breakpoints, improving patient care. It also includes an ABL1 mutation detection feature that eliminates the need for an additional testing step. The product comes with an automated analysis software that can be integrated into the laboratory's information system or the practice's electronic medical records system.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 1:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.